JUV-112 by Juvena Therapeutics: status and timeline

JUV-112

Enable weight loss by directly targeting adipose tissue metabolism, offering an alternative to appetite-suppressing drugs for obesity treatment.

ResearchStage 1 of 5

Preclinical: demonstrates weight loss via fat breakdown in animal models without appetite loss.

Checked 11 Oct0 updates this week

Milestones

Next · IND-enabling studies underway

Preclinical efficacy demonstrated in weight loss and fat reduction2025Complete.
IND-enabling studies underwayTarget 2026Current milestone.

Upcoming

2026IND-enabling studies underway (next)

Current obstacles

Unproven mechanism in humansThe lipolysis pathway and dosing that work in preclinical models may not translate to safe, effective human obesity treatment.

Physics limits

Energy regulation complexityThe central nervous system integrates multiple signals controlling appetite and expenditure; a single protein target may have limited effect if compensatory mechanisms engage.

How it works

2 parts

Lipolysis Inducer

Direct fat-cell activation

JUV-112 acts on adipose tissue to increase fat breakdown and energy expenditure, bypassing appetite centers.

Muscle Sparing

Preserves lean mass

Unlike GLP-1 drugs that reduce intake and cause lean-mass loss, JUV-112 targets fat specifically.

About Juvena Therapeutics

The team behind JUV-112

Juvena Therapeutics

JUV-161 muscle regeneration, JUV-112 obesity

Juvena Therapeutics develops engineered proteins from stem cell secretomes for tissue regeneration. Lead program JUV-161 is in Phase 1 for muscle atrophy. Eli Lilly partnership values $650 million collaboration focused on frailty and obesity.

JUV-161 is in Phase 1 trials for muscle regeneration with an orphan designation for myotonic dystrophy.
Eli Lilly partnership worth $650M targets frailty and obesity using Juvena's AI-driven discovery platform.
JUV-112 preclinical candidate promotes fat breakdown without appetite suppression or muscle loss.

juvenatherapeutics.com (opens juvenatherapeutics.com)Company profile →

Founded: 20179 yrs
Headquarters: United States
Status: Private
Valuation: private
Raised: $75M2 rounds
Last round: Series B · $34MJan 2026
Works in: LongevityAnti-aging drugs
Coverage: 2 programs · 2 updateslatest 12 Jan 2026checked 11 Oct
Lead investors: Bison Ventures
Partners: Eli Lilly and Company (opens lilly.com)
People: Hanadie YousefCo-founderJeremy O'ConnellCo-founder